newsfilter
← Latest News
GlobeNewswire·

Serina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

  • Independent Safety Monitoring Committee recommended advancing SER-252 in Parkinson's disease to Cohort 2
  • Dosing for the registrational study's Cohort 2 has been initiated to evaluate higher dose levels
  • Topline single-ascending-dose data from the study is expected in the first half of 2027
  • Cohort 1 blinded pharmacokinetic data showed sustained drug exposure consistent with prolonged apomorphine delivery goals
  • Cohort 1 exploratory assessments identified sustained periods of motor function improvement in individual patients
  • Total operating expenses for the third quarter ended September 30, 2026, were $8.0 million, up from $6.4 million in 2025
  • Research and development expenses increased to $4.6 million in the third quarter of 2026 from $3.6 million in 2025
  • General and administrative expenses rose to $3.3 million in the third quarter of 2026 from $2.7 million in 2025
  • Net loss attributable to Serina common stockholders was $7.9 million ($0.31 per share) for the third quarter ended September 30, 2026
  • Cash and cash equivalents totaled $19.4 million as of September 30, 2026
  • SER-252 is an investigational apomorphine therapy using the POZ Platform designed to provide continuous dopaminergic stimulation
  • The registrational study is a randomized, double-blind, placebo-controlled trial with single-ascending-dose and multiple-ascending-dose components
  • The trial is conducted across sites in the U.S. and Australia with oversight by an independent Safety Monitoring Committee
Company
Serina Therapeutics, Inc.
Keywords
NYSE:SER, Serina Therapeutics, Inc., Serina Therapeutics, Inc, NYSE American: SER, clinical-stage biotechnology, POZ Platform™, drug optimization technology